February 3, 2014 / 9:44 PM / 4 years ago

UPDATE 1-Edwards Lifesciences net down on costs

Feb 3 (Reuters) - Medical device maker Edwards Lifesciences Corp said on Monday that fourth-quarter net earnings declined from a year ago due to restructuring charges and costs for launching its next-generation replacement heart valves.

Excluding special items, earnings topped analysts' expectations on stronger sales of its transcatheter heart valves that are implanted in a less-invasive procedure than traditional open-heart surgery.

The medical device maker said net income fell to $75.8 million, or 68 cents a share, from $91.1 million, or 77 cents a share, a year earlier.

Excluding special items, Edwards earned 91 cents a share.

Fourth-quarter net sales rose 5 percent to $536 million. Sales of transcatheter heart valves, which are threaded into place with a catheter through the arteries, climbed 14.2 percent to $183.9 million.

Edwards said it still expects 2014 earnings, excluding items, in a wide range around $3.00 per share, on sales of $2.05 billion to $2.25 billion.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below